The Research Animal Support Facility (RASF) has been a shared resource since the original CCSG wasawarded in 1975 and exists to support ongoing clinical and basic cancer research involving laboratoryanimals at MDACC. The RASF has components located in Houston at MDACC (2 campuses), and inSmithville in the Department of Carcinogenesis. All animal facilities are accredited by the Association for theAssessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assuranceapproval (A3343-01), and are registered as research animal facilities with the United States Department ofAgriculture (USDA) (74-R-065). The Research Animal Support Facility Houston (RASFH) is directed byPeggy T. Tinkey, D.V.M. The RASFH encompasses approximately 99,089 sq. ft. of space and provideshousing, procedure space, veterinary care, and quality assurance programs for animals used in cancerresearch. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services areprovided. Existing technical services have been extended to the South Campus facility, and new servicesadded since the last CCSG renewal include computerized animal pedigree and medical history applications,preclinical toxicology services, and increased transportation services. New equipment includes automatedmulti-species hematology and chemistry analyzers, patient monitoring systems, automated beddingdispensing systems and waste containers, cargo van, and 100 ventilated rodent rack/cage systems. TheRASFH has 122 personnel, which includes 11 veterinarians, 2 associate directors, 1 administrator, 2 sectionmanagers, 1 project manager, 10 laboratory personnel, 77 animal care personnel, and 17 clerical/supportstaff. Dr. Tinkey coordinates the daily operations of the RASFH. Five faculty veterinarians direct the 5service sections that provide facilities, equipment, and services to research animal users. Funding for theRASFH is currently provided by the CCSG (6%), user fees (39%), institutional support (53%) and other funds(2%). In the past 5 years, the RASFH has been used by 319 investigators supporting 20 different CCSGprograms. Peer-reviewed investigators represent 92% of the RASFH user utilization. The majority ofanimals used are genetically engineered mice. In the past 5 years, the daily average cage counts increased52%, from 13,243 cages in 2002-03 to 20,132 cages of animals in 2006-07. Future plans include renovationand expansion of the South Campus animal facility, and upgrading and implementing computer applicationsfor business operations and preclinical drug development. Additionally, RASF-Houston and Smithville havejointly submitted a startup proposal to develop a Mutant Mouse Pathology Service to serve all MDACCinvestigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-33
Application #
7695934
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-28
Project End
2013-06-30
Budget Start
2008-08-28
Budget End
2009-06-30
Support Year
33
Fiscal Year
2008
Total Cost
$819,948
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Hui, David; Hess, Kenneth; Dibaj, Seyedeh S et al. (2018) The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer 124:2246-2252
LeBleu, Valerie S; Kalluri, Raghu (2018) A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech 11:
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8
Saintigny, Pierre; Mitani, Yoshitsugu; Pytynia, Kristen B et al. (2018) Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124:3693-3705
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Saltz, Joel; Gupta, Rajarsi; Hou, Le et al. (2018) Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23:181-193.e7
Dondossola, Eleonora; Alexander, Stephanie; Holzapfel, Boris M et al. (2018) Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10:
Yue, Jinbo; Shi, Qiuling; Xu, Ting et al. (2018) Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 27:1563-1570
Allen, Julie K; Armaiz-Pena, Guillermo N; Nagaraja, Archana S et al. (2018) Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res 78:3233-3242
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240

Showing the most recent 10 out of 12418 publications